Vis enkel innførsel

dc.contributor.authorLandmark, Cecilie Johannessen
dc.contributor.authorSvendsen, Torleiv
dc.contributor.authorDinarevic, Jasmin
dc.contributor.authorKufaas, Ruben F.
dc.contributor.authorReimers, Arne
dc.contributor.authorBrodtkorb, Eylert
dc.contributor.authorBaftiu, Arton
dc.contributor.authorBurns, Margrete Larsen
dc.contributor.authorJohannessen, Svein Ivar
dc.date.accessioned2017-10-30T08:08:18Z
dc.date.available2017-10-30T08:08:18Z
dc.date.created2016-08-25T12:30:38Z
dc.date.issued2016
dc.identifier.citationTherapeutic Drug Monitoring. 2016, 38 (4), 499-505.nb_NO
dc.identifier.issn0163-4356
dc.identifier.urihttp://hdl.handle.net/11250/2462693
dc.description.abstractBackground: Eslicarbazepine acetate (ESL) is a new anti-epileptic drug (AED) chemically related to oxcarbazepine (OXC) and carbamazepine (CBZ) and is increasingly used in clinical practice. The purpose of the study was to investigate 2-way pharmacokinetic interactions between ESL and other AEDs as compared to OXC and CBZ. Methods: Anonymous data regarding age, gender, use of AEDs, daily doses and serum concentration measurements of ESL, OXC, CBZ and lamotrigine (LTG) and other AEDs were retrieved from 2 therapeutic drug monitoring (TDM) databases in Norway. Drugs were categorized according to their known potential for interactions. Concentration/dose (C/D) ratios were calculated. Results: Data from 1100 patients were available. The C/D ratios of ESL and OXC were unchanged in combination with enzyme-inducing AEDs or valproate (VPA). The C/D ratio of CBZ decreased by 40% and 22% in combination with other enzyme-inducing AEDs or VPA, respectively, pointing to an increased clearance. ESL demonstrated no significant enzyme-inducing effect on LTG metabolism although there was a 20% and 34% decrease in the C/D ratio of LTG in combination with OXC and CBZ, respectively. Conclusions: Possible pharmacokinetic interactions have been studied for ESL as compared to OXC and CBZ. The pharmacokinetics of ESL is not affected by enzyme-inducing AEDs or VPA and does not affect the metabolism of LTG in contrast to OXC and CBZ. The study demonstrates the value of using TDM databases to explore the potential for pharmacokinetic interactions of new AEDs.nb_NO
dc.language.isoengnb_NO
dc.publisherLippincott, Williams & Wilkinsnb_NO
dc.titleThe Impact of Pharmacokinetic Interactions with Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practicenb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber499-505nb_NO
dc.source.volume38nb_NO
dc.source.journalTherapeutic Drug Monitoringnb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.1097/FTD.0000000000000306
dc.identifier.cristin1375461
dc.description.localcodeCopyright © 2016 Wolters Kluwer Health, Inc. This article will not be available due to copyright restrictions.nb_NO
cristin.unitcode194,65,10,0
cristin.unitcode194,65,30,0
cristin.unitnameInstitutt for laboratoriemedisin, barne- og kvinnesykdommer
cristin.unitnameInstitutt for nevromedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel